Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in C:\inetpub\wwwroot\technology_detail.php on line 331
 Technology Detail


The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

Methods to improve survival from heart failure in chronic hypertension and to prevent arterial stenosis


Stanford Reference:

06-137


Abstract


Approximately 5 million people in the United States suffer from heart failure. Stanford inventors in the laboratory of Dr. Daria Mochly-Rosen have developed a method for treating heart failure using a peptide inhibitor of a specific protein kinase C (PKC) isozyme.

Using a rat model for hypertension, the inventors demonstrated that the peptide slowed the progress of heart failure. The peptide in combination with an angiotension II receptor blocker (ARB) showed improved outcomes over treatment with the ARB alone. The inhibitor was also used in a post-MI model of heart failure, demonstrating similar benefit including: improved cardiac function, reduced death, and improved calcium handling.

The treatment appears safe in healthy animals and proved beneficial in diabetic animals. Therefore, it may exert further benefit in patients with heart failure who also have diabetes. Further evidence suggests that the peptide could have potential applications in treating arterial stenosis.



Applications


  • Treatment for heart failure - alone or as a combination therapy
  • Treatment for arterial stenosis

Advantages


  • Novel Treatment
  • Benefits Expected For Multiple Patient Populations

Publications



Web Site


Mochly-Rosen Lab

Related Web Links



Innovators & Portfolio



Patent Status



Date Released

 7/23/2012
 

Licensing Contact


Sara Nakashima, Licensing Associate
650 725 9115 (Direct)
Login to Request Information

[-] Map/Timeline

92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
93-168 Peptides That Modulate Interaction Between PKC and RACK
96-103 εPKC Agonists to Provide Cardioprotection

more technologies »

Related Keywords


therapeutic: peptides   Hypertension   heart failure   cardiovascular   arterial stenosis   top pharma companies   
 

   

  

Also of Interest...
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
93-168 Peptides That Modulate Interaction Between PKC and RACK
96-103 εPKC Agonists to Provide Cardioprotection

Recently Viewed...
S06-137 Methods to improve survival from heart failure in chronic hypertension and to prevent arterial stenosis